To evaluate the developmental pattern of ABO isohemagglutinins in Taiwanese, 644 blood samples (349 males, 295 females), including cord blood, were collected from individuals with ages ranging from newborn to 83 years. Synthesis of anti-A and anti-B could be demonstrated in most Taiwanese infants by 2-4 months of age, increasing progressively to reach adult levels (titers of 1:32-1:256) at around 1 year of age. Peak levels were reached at between 3-10 years of age and then declined with advancing years, with individuals of 80 years of age and over showing reduced levels similar to those seen in 6- to 12-month-old infants. Sex and parity did not appear to influence ABO isohemagglutinin development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000154350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of ABO Mismatch and Red Blood Cell Alloimmunization on the Outcome of Hematopoietic Cell Transplantation for Sickle Cell Disease.
Transplant Cell Ther
January 2025
Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Ministry of National Guards-Health Affairs, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Saudi Scientific Society of Blood and Marrow Transplantation, Jeddah, Saudi Arabia. Electronic address:
Article Synopsis
- * ABO blood group mismatch and alloimmunization can significantly affect the success of HCT in SCD patients, leading to complications like hemolysis and graft failure.
- * This study analyzed data from 194 SCD patients over 14 years old who underwent HCT and focused on the effects of RBC incompatibility and alloimmunization on transplant outcomes and overall survival.
Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation.
Eur J Haematol
February 2025
Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.
Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti-donor isohemagglutinins leads to reticulocytopenia and anemia, often resulting in transfusion dependence. Current treatment options for post-HSCT PRCA are limited and frequently yield suboptimal responses, complicating patient management.
View Article and Find Full Text PDFDetection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles.
Nanomedicine (Lond)
October 2024
Institute of Biomedicine, University of Turku, Turku, 20520, Finland.
Fluorescence detection of breast and prostate cancer cells expressing Tn-antigen, a tumor marker, with lectin (VVL)-labeled nanoparticles. Breast and prostate cancer cells engineered to express high levels of Tn-antigen and non-engineered controls were incubated with VVL-labeled or unlabeled red dye-doped silica-coated polystyrene nanoparticles. The binding to cells was studied with flow cytometry, confocal microscopy, and electron microscopy.
View Article and Find Full Text PDFComparison of manual titrations to automated microplate and gel titration assays used in the screening of blood donors for production of Low-Titer O Whole Blood.
Transfusion
October 2024
Transfusion Medicine Department, Eglin Air Force Base, Florida, USA.
Background: The popularity of Low-Titer O Whole Blood (LTOWB) for treating trauma patients requires that donor centers and transfusion services make decisions on what titer testing capabilities to institute and an appropriate titer level threshold. This study compared the titer results determined by four methods to find a rate of agreement.
Study Design And Methods: Isohemagglutinin titers were tested on 300 plasma samples utilizing various methods, each determining IgM antibody levels by direct hemagglutination with A1 and B reference cells.
Inclusive ABO-Incompatible Listing for Pediatric Heart Transplantation Results in Comparable Post-Transplant Rejection-Free Survival in a Single-Center Series.
Pediatr Cardiol
August 2024
Children's Hospital of Colorado, 13123 East 16th Ave., B200, Aurora, CO, 80045, USA.
ABO-incompatible (ABOi) heart transplantation (HT) has increased organ availability for infants with end-stage heart failure. Despite increasing adoption of ABOi listing for HT, data remain limited regarding pre- and post-HT immunologic profiles to guide listing practices and post-HT follow-up. Thus, the purpose of this study was to evaluate post-HT outcomes at a single center employing inclusive ABOi listing irrespective of pre-HT isohemagglutinin titers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!